1.Wysong, A, Aasi, SZ, Tang, JY. Update on metastatic basal cell carcinoma: A summary of published cases from 1981 through 2011. JAMA Dermatol 2013;149(5):615–16.
2.Beer, TW, Shepherd, P, Theaker, JM. BerEP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology 2000;37(3):218–23.
3.LeBoit, PE, Burg, G, Weedon, D, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press, 2006.
4.Kurzen, H, Esposito, L, Langbein, L, Hartschuh, W. Cytokeratins as markers of follicular differentiation: An immunohistochemical study of trichoblastoma and basal cell carcinoma. Am J Dermatopathol 2001;23(6):501–9.
5.Onishi, T, Watanabe, S. Immunohistochemical analysis of cytokeratin expression in various trichogenic tumors. Am J Dermatopathol 1999;21(4):337–43.
6.Evangelista, MT, North, JP. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma. J Cutan Pathol 2015;42(11):824–31.
7.Costache, M, Bresch, M, Boer, A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: A critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology 2008;52(7):865–76.
8.Katona, TM, Perkins, SM, Billings, SD. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol 2008;35(2):174–79.
9.Krahl, D, Sellheyer, K. p75 neurotrophin receptor differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: Insights into the histogenesis of adnexal tumours based on embryology and hair follicle biology. Br J Dermatol 2010;163(1):138–45.
10.Yeh, I, McCalmont, TH, LeBoit, PE. Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma. Br J Dermatol 2012;167(5):1106–10.
11.Pham, TTN, Selim, MA, Burchette, JL, et al. CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol 2006;33(2):123–28.
12.Chiller, K, Passaro, D, Scheuller, M, et al. Microcystic adnexal carcinoma: Forty-eight cases, their treatment, and their outcome. Arch Dermatol 2000;136(11):1355–59.
13.Tse, JY, Nguyen, AT, Le, LP, Hoang, MP. Microcystic adnexal carcinoma versus desmoplastic trichoepithelioma: A comparative study. Am J Dermatopathol 2013;35(1):50–55.
14.Sellheyer, K, Nelson, P, Kutzner, H, Patel, RM. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol 2013;40(4):363–70.
15.Hoang, MP, Dresser, KA, Kapur, P, High, WA, Mahalingam, M. Microcystic adnexal carcinoma: An immunohistochemical reappraisal. Mod Pathol 2008;21(2):178–85.
16.Smith, KJ, Williams, J, Corbett, D, Skelton, H. Microcystic adnexal carcinoma: An immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol 2001;25(4):464–71.
17.Carvalho, J, Fullen, D, Lowe, L, Su, L, Ma, L. The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol 2007;34(9):693–98.
18.Bogner, PN, Su, LD, Fullen, DR. Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. J Cutan Pathol 2005;32(1):50–54.
19.Vidal, CI, Goldberg, M, Burstein, DE, Emanuel, HJ, Emanuel, PO. P63 immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors. Am J Dermatopathol 2010;32(3):257–61.
20.Jedrych, J, McNiff, JM. Expression of p75 neurotrophin receptor in desmoplastic trichoepithelioma, infiltrative basal cell carcinoma, and microcystic adnexal carcinoma. Am J Dermatopathol 2013;35(3):308–15.
21.Kurokawa, I, Nishijima, S, Kusumoto, K, et al. Trichilemmoma: An immunohistochemical study of cytokeratins. Br J Dermatol 2003;149(1):99–104.
22.Illueca, C, Monteagudo, C, Revert, A, et al. Diagnostic value of CD34 immunostaining in desmoplastic trichilemmoma. J Cutan Pathol 1998;25(8):435–39.
23.Dalton, SRLeBoit, PE. Squamous cell carcinoma with clear cells: How often is there evidence of tricholemmal differentiation? Am J Dermatopathol 2008;30(4):333–39.
24.Fan, YS, Carr, RA, Sanders, DS, et al. Characteristic BerEP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology 2007;31(1):80–86.
25.Shields, JA, Demirici, H, Marr, BP, Eagle, RC Jr, Shields, CL. Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthalmology 2004;111(12):2151–57.
26.Asadi-Amoli, F, Khoshnevis, F, Haeri, H, et al. Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol 2010;134(1):22–26.
27.Ansai, S, Koseki, S, Hozumi, Y, Kondo, S. An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Am J Dermatopathol 1995;17(3):249–55.
28.Ostler, DA, Prieto, VG, Reed, JA, et al. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: An immunohistochemical study of 117 cases. Mod Pathol 2010;23(4):567–73.
29.Sramek, B, Lisle, A, Loy, T. Immunohistochemistry in ocular carcinomas. J Cutan Pathol 2008;35(7):641–46.
30.Sinard, JH. Immunohistochemical distinction of ocular sebaceous carcinoma from basal cell and squamous cell carcinoma. Arch Ophthalmol 1999;117(6):775–83.
31.Boussahmain, C, Mochel, MC, Hoang, MP. Perilipin and adipophilin expression in sebaceous carcinoma and mimics. Hum Pathol 2013;44(9):1811–16.
32.Shikata, N, Kurokawa, I, Andachi, H, et al. Expression of androgen receptors in skin appendage tumors: An immunohistochemical study. J Cutan Pathol 1995;22(2):149–53.
33.Ansai, S, Arase, S, Kawana, S, Kimura, T. Immunohistochemical findings of sebaceous carcinoma and sebaceoma: Retrieval of cytokeratin expression by a panel of anti-cytokeratin monoclonal antibodies. J Dermatol 2011;38(10):951–58.
34.Robson, A, Greene, J, Ansari, N, et al. Eccrine porocarcinoma (malignant eccrine poroma): A clinicopathologic study of 69 cases. Am J Surg Pathol 2001;25(6):710–20.
35.Mahalingam, M, Richards, JE, Selim, MA, Muzikansky, A, Hoang, MP. An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma. Hum Pathol 2012;43(8):1265–72.
36.Mahomed, F, Blok, J, Grayson, W. The squamous variant of eccrine porocarcinoma: A clinicopathological study of 21 cases. J Clin Pathol 2008;61():361–65.
37.Dotto, JE, Glusac, EJ. P63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol 2006;33(6):413–17.
38.Alomari, AK, Glusac, EJ, McNiff, JM. p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. J Cutan Pathol 2014;41(11):839–45.
39.Sigel, JE, Skacel, M, Bergfeld, WF, et al. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol 2001;28(10):520–24.
40.Heyderman, E, Graham, RM, Chapman, DV, Richardson, TC, McKee, PH. Epithelial markers in primary skin cancer: An immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathology 1984;8(3):423–34.
41.Beer, TW, Shepherd, P, Theaker, JM. Ber-EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology 2000;37(3):218–23.
42.Ansai, S, Koseki, S, Hozumi, Y, Kondo, S. An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Am J Dermatopathol 1995;17(3):249–55.
43.Goh, SGN, Dayrit, JF, Calonje, E. Sarcomatoid eccrine porocarcinoma: Report of two cases and a review of the literature. J Cutan Pathol 2007;34(1):55–60.
44.Qureshi, HS, Ormsby, A, Lee, MW, Zarbo, RJ, Ma, CK. The diagnostic utility of p63, CK5/6, CK7, and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. J Cutan Pathol 2004;31(2):145–52.
45.Pulitzer, M, Desman, G, Busam, KJ. CK7 expression in primary cutaneous squamous cell carcinoma. J Cutan Pathol 2010;37(9):966–72.
46.Mahalingam, M, Nguyen, LP, Richards, JE, Muzikansky, A, Hoang, MP. The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: An immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol 2010;23(5):713–19.
47.Kurokawa, I, Urakawa, Y, Senba, Y, et al. Keratin profiles may differ between intraepidermal and intradermal invasive eccrine porocarcinoma. Oncol Rep 2006;16(3):473–77.
48.Chen, S, Takahara, M, Kido, M, et al. Increased expression of an epidermal stem cell marker, cytokeratin 19, in cutaneous squamous cell carcinoma. Br J Dermatol 2008;159(4):952–55.
49.Yada, K, Kashima, K, Daa, T, et al. Expression of CD10 in basal cell carcinoma. Am J Dermatopathol 2004;26(6):463–71.
50.Lee, JJ, Mochel, MC, Piris, A, et al. p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases. Hum Pathol 2014;45(5):1078–83.
51.Gu, LH, Ichiki, Y, Kitajima, Y. Aberrant expression of p16 and RB protein in eccrine porocarcinoma. J Cutan Pathol 2002;29(8):473–79.
52.Hernandez-Parez, E, Cestoni-Parducci, R. Nodular hidradenoma and hidradenocarcinoma. A 10-year review. J Am Acad Dermatol 1985;12(1 Pt 1):15–20.
53.Nazarian, RM, Kapur, P, Rakheja, D, et al. Atypical and malignant hidradenomas: A histologic and immunohistochemical study. Mod Pathol 2009;22(4):600–10.
54.Mambo, NC. The significance of atypical nuclear changes in benign eccrine acrospiromas: A clinical and pathological study of 18 cases. J Cutan Pathol 1984;11(1):35–44.
55.Young, AW Jr, Herman, EW, Tovell, HM. Syringoma of the vulva: Incidence, diagnosis, and cause of pruritus. Obstet Gynecol 1980;55(4):515–18.
56.Kazakov, DV, Bouda, J Jr, Kacerovska, D, Michal, M. Vulvar syringomas with deep extension: A potential histopathologic mimic of microcystic adnexal carcinoma. Int J Gynecol Pathol 2011;30(1):92–94.
57.Missall, TA, Burkemper, NM, Jensen, SL, Hurley, MY. Immunohistochemical differentiation of four benign eccrine tumors. J Cutan Pathol 2009;36(2):190–96.
58.Wallace, ML, Smoller, BR. Progesterone receptor positivity supports hormonal control of syringomas. J Cutan Pathol 1995;22(5):442–45.
59.Kazakov, DV, Suster, S, LeBoit, PE, et al. Mucinous carcinoma of the skin, primary, and secondary: A clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: Homologies with mucinous lesions in the breast. Am J Surg Pathol 2005;29(6):764–82.
60.Qureshi, HS, Salama, ME, Chitale, D, et al. Primary cutaneous mucinous carcinoma: Presence of myoepithelial cells as a clue to the cutaneous origin. Am J Dermatopathol 2004;26(5):353–58.
61.Levy, G, Finkelstein, A, McNiff, JM. Immunohistochemical techniques to compare primary vs. metastatic mucinous carcinoma of the skin. J Cutan Pathol 2010;37(4):411–15.
62.Zembowicz, A, Garcia, CF, Tannous, ZS, et al. Endocrine mucin-producing sweat gland carcinoma. Twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas. Am J Surg Pathol 2005;29(10):1330–39.
63.Mortensen, AL, Heegaard, S, Clemmensen, O, Prause, JU. Signet ring cell carcinoma of the eyelid – the monocle tumour. APMIS 2008;116(4):326–32.
64.Requena, L, Prieto, VG, Requena, C, et al. Primary signet-ring cell/histiocytoid carcinoma of the eyelid: A clinicopathologic study of 5 cases and review of the literature. Am J Surg Pathol 2011;35(3):378–91.
65.Robson, A, Lazar, AJ, Ben Nagi, J, et al. Primary cutaneous apocrine carcinoma: A clinicopathologic analysis of 24 cases. Am J Surg Pathol 2008;32(5):682–90.
66.Japaze, H, Imina, J, Diaz, C, et al. “Pure” invasive apocrine carcinoma of the breast: A new clinicopathological entity? Breast 2005;14(1):3–10.
67.Celis, JE, Cabezon, T, Moreira, JMA, et al. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 2009;3(3):220–37.
68.Niemeier, LA, Dabbs, DJ, Beriwal, S, Striebel, JM, Bhargava, R. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010;23(2):205–12.
69.Le, LP, Dias-Santagata, D, Pawlak, AC, et al. Apocrine-eccrine carcinomas: Molecular and immunohistochemical analyses. PLoS One 2012;7(10):e47290. doi: 10.1371/journal.pone.0047290.
70.Piris, A, Peng, Y, Boussahmain, C, et al. Cutaneous and mammary apocrine carcinomas have different immunoprofiles. Hum Pathol 2014;45(2):320–26.
71.Plumb, SJ, Argenyi, ZB, Stone, MS, De Young, BR. Cytokeratin 5/6 immunostaining in cutaneous adnexal neoplasms and metastatic adenocarcinoma. Am J Dermatopathol 2004;26(6):447–51.
72.Chanda, JJ. Extramammary Paget’s disease: Prognosis and relationship to internal malignancy. J Am Acad Dermatol 1985;13(6):1009–14.
73.Shepherd, V, Davidson, EJ, Davies-Humphreys, J. Extramammary Paget’s disease. BJOG 2005;112(3):273–79.
74.Lam, C, Funaro, D. Extramammary Paget’s disease: Summary of current knowledge. Dermatol Clin 2010;28(4):807–26.
75.Goldblum, JR, Hart, WR. Perianal Paget’s disease: A histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol 1998;22(2):170–79.
76.De Nisi, MC, D’Amuri, A Toscano, M, Lalinga, AV, Pirtoli, L, Miracco, C. Usefulness of CDX2 in the diagnosis of extramammary Paget disease associated with malignancies of intestinal type. Br J Dermatol 2005;153(3):677–79.
77.Ohnishi, T, Watanabe, S. The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget’s disease. Br J Dermatol 2000;142(2):243–47.
78.Perrotto, J, Abbott, JJ, Ceilley, RI, Ahmed, I. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget’s disease. Am J Dermatopathol 2010;32(2):137–43.
79.Brown, HM, Wilkinson, EJ. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum Pathol 2002;33(5):545–48.
80.Plaza, JA, Torres-Cabala, C, Ivan, D, Prieto, VG. HER-2/neu expression in extramammary Paget disease: A clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J Cutan Pathol 2009;36(7):729–33.
81.Liegl, B, Horn, HC. Moinfar, F. Androgen receptors are frequently expressed in mammary and extramammary Paget’s disease. Mod Pathol 2005;18(10):1283–88.
82.Hikita, T, Ohtsuki, Y, Maeda, T, Furihata, M. Immunohistochemical and fluorescence studies on noninvasive and invasive extramammary Paget’s disease. Int J Surg Pathol 2012;20(5):441–48.
83.Kuan, S-F, Montag, AG, Hart, J, Krausz, T, Recant, W. Differential expression of mucin genes in mammary and extramammary Paget’s disease. Am J Surg Pathol 2001;25(12):1469–77.
84.Shaco-Levy, R, Bean, SM, Vollmer, RT, et al. Paget disease of the vulva: A histologic study of 56 cases correlating pathologic features and disease course. Int J Gynecol Pathol 2010;29(1):69–78.
85.Chang, J, Prieto, VG, Sangueza, M, Plaza, JA. Diagnostic utility of p63 expression in the differential diagnosis of pagetoid squamous cell carcinoma in situ and extramammary Paget disease: A histopathologic study of 70 cases. Am J Dermatopathol 2014;36(1):49–55.
86.Wollina, U, Graefe, T, Konrad, H, Schönlebe, J. Cutaneous metastases of internal cancer. Acta Dermatoven APA 2004;13(3):79–84.
87.Reis-Filho, JS, Torio, B, Albergaria, A, Schmitt, FC. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 2002;29(9):517–23.
88.Ivan, D, Diwan, A, Prieto, VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol 2005;18(1):137–42.
89.Rollins-Raval, M, Chivukula, M, Tseng, GC, Jukic, D, Dabbs, DJ. An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature. Arch Pathol Lab Med 2011;135(8):975–83.
90.Chang, A, Amin, A, Gabrielson, E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012;36(10):1472–76.
91.North, JP, McCalmont, TH, Fehr, A, et al. Detection of MYB alterations and other immunohistochemical markers in primary cutaneous adenoid cystic carcinoma. Am J Surg Pathol 2015;39(10):1347–56.
92.Dessauvagie, BF, Wood, BA. CD117 and CD43 are useful adjuncts in the distinction of adenoid cystic carcinoma from adenoid basal cell carcinoma. Pathology 2015;47(2):130–33.
Emanuel, P, Wang, B, Wu, M, Burstein, DE. p63 immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol 2005;18(5):645–50.
93.Persson, M, Andren, Y, Mark, J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Nalt Acad Sci USA 2009;106(44):18740–44.
94.Von Holstein, SL, Fehr, A, Persson, M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology 2013;210(10):2130–38.
95.Mitani, Y, Li, J, Rao, PH, Zhao, YJ, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability and clinicopathologic significance. Clin Cancer Res 2010;16(19):4722–31.
96.West, RB, Kong, C, Clarke, N, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011;35(1):92–9.
97.Bell, D, Roberts, D, Karpowicz, M, et al. Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biol Ther 2011;12(7):569–73.
98.Brill, LB, Kanner, WA, Fehr, A, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 2011;24(9):1169–76.
99.Bullerdiek, J, Wobst, G, Meyer-Bolte, K, et al. Cytogenetic subtyping of 220 salivary gland pleomorphic adenomas: Correlation to occurrence, histological subtype, and in vitro cellular behavior. Cancer Genet Cytogenet 1993;65(1):27–32.
100.Matsuyama, A, Hisaoka, M, Nagao, Y, Hashimoto, H. Aberrant PLAG1 expression in pleomorphic adenomas of the salivary gland: A molecular genetic and immunohistochemical study. Virchows Arch 2011;458(5):583–92.
101.Matsuyama, A, Hisaoka, M, Hashimoto, H. PLAG1 expression in cutaneous mixed tumors: An immunohistochemical and molecular genetic study. Virchows Arch 2011;459(5):539–45.
102.Matsuyama, A, Hisaoka, M, Hashimoto, H. PLAG1 expression in mesenchymal tumors: An immunohistochemical study with special emphasis on the pathogenetical distinction between soft tissue myoepithelioma and pleomorphic adenoma of the salivary gland. Pathol Int 2012;62(1):1–7.
103.Bahrami, A, Dalton, JD, Shivakumar, B, Krane, JF. PLAG1 alteration in carcinoma ex pleomorphic adenoma: Immunohistochemical and fluorescence in situ hybridization studies of 22 cases. Head Neck Pathol 2012;6(3):328–35.
104.Mendoza, PR, Jakobiec, FA, Krane, JF. Immunohistochemical features of lacrimal gland epithelial tumors. Am J Ophthalmol 2013;156(6):1147–58.
105.Snow, SN, Reizner, GT. Mucinous eccrine carcinoma of the eyelid. Cancer 1992;70(8):2099–104.
106.Hanby, AM, McKee, P, Jeffery, M, et al. Primary mucinous carcinoma of the skin express AFF1, TFF3, estrogen receptor, and progresterone receptors. Am J Surg Pathol 1998;22(9):1125–31.
107.Rahilly, MA, Beattie, GJ, Lessels, AM. Mucinous eccrine carcinoma of the vulva with neuroendocrine differentiation. Histopathology 1995;27(1):82–86.
108.Pardal, J, Sundram, U, Selim, MA, Hoang, MP. GATA3 and MYB expression in cutaneous adnexal neoplasms. Am J Dermatopathol 2017;39(4):279–86.
109.Bigby, SM, Charlton, A, Miller, MV, et al. Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): Four cases with immunohistochemistry and review of the literature. J Cutan Pathol 2005;32(2):141–47.
110.McKee, PH, Fletcher, CDM, Stavrinos, P, Pambakian, H. Carcinosarcoma arising in eccrine spiradenoma. A clinicopathological and immunohistochemical study of two cases. Am J Dermatopathol 1990;12(4):335–43.
111.Patel, NK, McKee, PH, Smith, NP, Fletcher, CD. Primary metaplastic carcinoma (carcinosarcoma) of the skin. A clinicopathologic study of four cases and review of the literature. Am J Dermatopathol 1997;19(4):363–72.
112.Brasanac, D, Boricic, I, Todorovic, V, Tomanovic, N. Primary cutaneous carcinosarcoma: Case report with expanded immunohistochemical analysis. Int J Dermatol 2008;47(5):496–501.
113.Tran, TA, Muller, S, Chaudahri, PJ, Carlson, JA. Cutaneous carcinosarcoma: Adnexal vs. epidermal types define high- and low-risk tumors. Results of a meta-analysis. J Cutan Pathol 2005;32(1):2–11.
114.Paniz-Mondolfi, A, Singh, R, Jour, G, et al. Cutaneous carcinosarcoma: Further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch 2014;465(3):339–50.
115.Thompson, L, Chang, B, Barsky, SH. Monoclonal origins of malignant mixed tumors (carcinosarcoma): Evidence for a divergent histogenesis. Am J Surg Pathol 1996;20(3):277–85.
116.Boyd, AS, Rapini, RP. Cutaneous collision tumors: An analysis of 69 cases and review of the literature. Am J Dermatopathol 1994;16(3):253–57.
117.Burkhalter, A, White, W. Malignant melanoma in situ colonizing basal cell carcinoma: A simulator of invasive melanoma. Am J Dermatopathol 1997;19(3):303–7.
118.Rodriguez, J, Nonaka, D, Kuhn, E, et al. Combined high-grade basal cell carcinoma and malignant melanoma of the skin (“malignant basomelanocytic tumor”): Report of two cases and review of the literature. Am J Dermatopathol 2005;27(4):314–18.
119.Goeser, M, DiMaio, DJ. A colonization of basal cell carcinoma by malignant melanoma in situ resembling a malignant basomelanocytic tumor. Am J Dermatopathol 2014;36(11):e179–e182.
120.Busam, KJ, Halpern, A, Marghoob, AA. Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor. Am J Surg Pathol 2006;30(1):133–36.
121.Erickson, LA, Myers, JL, Mihm, MC, Markovic, SN, Pittelkow, MR. Malignant basomelanocytic tumor manifesting as metastatic melanoma. Am J Surg Pathol 2004;28(10):1393–96.
122.Florell, SR, Zone, JJ, Gerwels, JW. Basal cell carcinomas are populated by melanocytes and Langerhans cells. Am J Dermatopathol 2001;23(1):24–28.
